๐ฐ Mapi Pharma News
Page 3 - Mapi Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mapi Pharma. Real-time updates on events, politics, business and more.
March 7, 2023
The long-acting glatiramer acetate therapy GA Depot was found to ease disability in patients with relapsing forms of MS in a Phase 3 trial.
November 23, 2022
New recommendations help clinicians communicate technical information to help patients with multiple sclerosis achieve better understanding and self-care.
November 7, 2022
Reaffirms 2022 Guidance Ranges [1] Across Total Revenues, Adjusted EBITDA and Free Cash Flow; Driven by Solid Operating Momentum Despite Foreign Exchange...
October 12, 2022
GA Depot is a Potential Long Acting Injection Solution for Multiple Sclerosis Patients Positive Results from Phase III GA Depot Study in Relapsing MS to...
December 21, 2021
The results found similar efficacy to existing treatments but with reduced side-effects such as less daytime drowsiness.
October 21, 2021
DUBAI, United Arab Emirates and NESS ZIONA, Israel, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. (โMapiโ or the โCompanyโ), a developer of...
October 18, 2021
ISRAEL21c compiles a list of the 10 most extraordinary medical devices and pharmaceuticals that promise to revolutionize global healthcare.
June 10, 2021
MRInsights.biz has rolled out a report titled Global Long-acting Injectable Medications Market Growth (Status and Outlook) 2021-2026 that is filled wi
April 13, 2021
5 (1) A Phase 3 trial investigating GA Depot, a long-acting, once-a-month injectable formulation of glatiramer acetate, is seeking patients with relapsing forms of multiple sclerosis (MS). Enrollment opened in 2019, with clinical sites in the U.S. and Eastern Europe added since then. More information on contacts and locations can be found here. People in the U.S. who are interested in participating can see if they are eligible here. GA Depot, developed by Mapi Pharma, is a...
February 25, 2021
ip eline drugs in the Primary Progressive Multiple Sclerosis pipeline landscapes. It comprises PPMS pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Primary Progressive Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive PPMS pipeline products.ย ย ย Some of the crucial features of the Primary Progressive Multiple Sclerosis key players such as Atara Bi...